| Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers F Cottini, T Hideshima, C Xu, M Sattler, M Dori, L Agnelli, E Ten Hacken, ... Nature medicine 20 (6), 599-606, 2014 | 313 | 2014 |
| General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL C Fazi, L Scarfò, L Pecciarini, F Cottini, A Dagklis, A Janus, A Talarico, ... Blood, The Journal of the American Society of Hematology 118 (25), 6618-6625, 2011 | 177 | 2011 |
| Histone deacetylase 3 as a novel therapeutic target in multiple myeloma J Minami, R Suzuki, R Mazitschek, G Gorgun, B Ghosh, D Cirstea, Y Hu, ... Leukemia 28 (3), 680-689, 2014 | 158 | 2014 |
| Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition M Cea, A Cagnetta, M Fulciniti, YT Tai, T Hideshima, D Chauhan, ... Blood, The Journal of the American Society of Hematology 120 (17), 3519-3529, 2012 | 153 | 2012 |
| Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma T Hideshima, J Qi, RM Paranal, W Tang, E Greenberg, N West, ... Proceedings of the National Academy of Sciences 113 (46), 13162-13167, 2016 | 124 | 2016 |
| Synthetic lethal approaches exploiting DNA damage in aggressive myeloma F Cottini, T Hideshima, R Suzuki, YT Tai, G Bianchini, PG Richardson, ... Cancer discovery 5 (9), 972-987, 2015 | 116 | 2015 |
| Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma T Hideshima, F Cottini, H Ohguchi, J Jakubikova, G Gorgun, N Mimura, ... Blood cancer journal 5 (5), e312-e312, 2015 | 73 | 2015 |
| Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma S Kikuchi, R Suzuki, H Ohguchi, Y Yoshida, D Lu, F Cottini, J Jakubikova, ... Leukemia 29 (9), 1918-1927, 2015 | 72 | 2015 |
| Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition N Mimura, T Hideshima, T Shimomura, R Suzuki, H Ohguchi, O Rizq, ... Cancer research 74 (16), 4458-4469, 2014 | 70 | 2014 |
| Monoclonal B cell lymphocytosis in hepatitis C virus infected individuals C Fazi, A Dagklis, F Cottini, L Scarfo, MTS Bertilaccio, R Finazzi, ... Cytometry Part B: Clinical Cytometry 78 (S1), S61-S68, 2010 | 67 | 2010 |
| Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and-independent anti-multiple myeloma activity through inhibition of transcriptional CDKs D Cirstea, T Hideshima, L Santo, H Eda, Y Mishima, N Nemani, Y Hu, ... Leukemia 27 (12), 2366-2375, 2013 | 54 | 2013 |
| Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma E Malek, MAY Abdel-Malek, S Jagannathan, N Vad, R Karns, AG Jegga, ... Leukemia 31 (3), 645-653, 2017 | 53 | 2017 |
| p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma T Hideshima, F Cottini, Y Nozawa, HS Seo, H Ohguchi, MK Samur, ... Blood, The Journal of the American Society of Hematology 129 (10), 1308-1319, 2017 | 52 | 2017 |
| Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma R Suzuki, T Hideshima, N Mimura, J Minami, H Ohguchi, S Kikuchi, ... Leukemia 29 (2), 510-514, 2015 | 36 | 2015 |
| Combination of a selective HSP90α/β inhibitor and a RAS-RAF-MEK-ERK signaling pathway inhibitor triggers synergistic cytotoxicity in multiple myeloma cells R Suzuki, S Kikuchi, T Harada, N Mimura, J Minami, H Ohguchi, ... PloS one 10 (12), e0143847, 2015 | 33 | 2015 |
| Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma D Cirstea, L Santo, T Hideshima, H Eda, Y Mishima, N Nemani, ... Molecular cancer therapeutics 13 (11), 2489-2500, 2014 | 28 | 2014 |
| Novel therapeutic targets in multiple myeloma F Cottini, K Anderson Clin Adv Hematol Oncol 13 (4), 236-248, 2015 | 27 | 2015 |
| Synthetic Lethal Approaches exploiting DNA damage in aggressive myeloma. Cancer Discov. 2015; 5 (9): 972–87. doi: 10.1158/2159-8290 F Cottini, T Hideshima, R Suzuki, YT Tai, G Bianchini, PG Richardson, ... CD-14-0943, 0 | 19 | |
| Awakening the Hippo co-activator YAP1, a mercurial cancer gene, in hematologic cancers F Cottini, KC Anderson, G Tonon Molecular & Cellular Oncology 1 (3), e970055, 2014 | 12 | 2014 |
| Improvement in post-autologous stem cell transplant survival of multiple myeloma patients: a long-term institutional experience J Nunnelee, F Cottini, Q Zhao, MS Faisal, P Elder, A Rosko, N Bumma, ... Cancers 14 (9), 2277, 2022 | 11 | 2022 |
